Advancell raised an oversubscribed $315 million Series D to accelerate its push to become a fully integrated global radiopharma developer. The financing is aimed at funding late-stage clinical development alongside isotope supply and manufacturing infrastructure. The strategy directly targets a common constraint in radiopharmaceutical development: the alignment of radionuclide availability with clinical timelines and commercial scale-up. By pairing clinical-stage investment with manufacturing and isotope logistics, Advancell’s model seeks to reduce delivery risk that can stall or delay program execution. The round also positions the company to strengthen its end-to-end capabilities across development and supply chains—an increasingly important factor for oncology-focused radiopharma programs.